Lead (Pb) and the Risk of Alzheimer's disease or cognitive decline: A systematic review

Toxin Reviews

Volumn 30, Issue 4, 2011, Pages 103-114

  Loef, Martin ^a,b   Mendoza, Luisa Fernanda ^a,c   Walach, Harald ^a,b  

^a EUROPEAN UNIVERSITY VIADRINA   (Germany)

^b European Office   (Germany)

^c UNIVERSIDAD DE LOS ANDES   (Colombia)

Author keywords

amyloid beta; dementia; early life exposure; Neurotoxicity; oxidative stress; tauopathy

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BETA SECRETASE 1; DNA METHYLTRANSFERASE 1; GLUTATHIONE; HFE PROTEIN; INSULINASE; LEAD; LEAD 210; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE C; RADON; TAU PROTEIN; THIOL GROUP; TRANSCRIPTION FACTOR SP1;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BLOOD LEVEL; BONE LEVEL; BRAIN LEVEL; CALCIUM SIGNALING; CEREBROSPINAL FLUID; CHOROID PLEXUS; COGNITIVE DEFECT; CONFUSION; DENTATE GYRUS; DIFFUSE NEUROFIBRILLARY TANGLES WITH CALCIFICATION; DIGIT SYMBOL TEST; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; ENZYME ACTIVITY; EXPOSURE; FRONTAL CORTEX; GENE EXPRESSION; GENETIC RISK; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; LEAD POISONING; MEMORY DISORDER; MENTAL PERFORMANCE; MENTAL STRESS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATELLA; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; REVIEW; RURAL AREA; SYSTEMATIC REVIEW; TEMPORAL CORTEX; TIBIA; TRANSCRIPTION REGULATION; UPREGULATION; WECHSLER INTELLIGENCE SCALE; WHITE MATTER;

EID: 83255193542     PISSN: 15569543     EISSN: 15569551     Source Type: Journal    
DOI: 10.3109/15569543.2011.624664     Document Type: Review

References (136)

1. Ahamed M, Siddiqui MK. (2007). Low level lead exposure and oxidative stress: current opinions. Clin Chim Acta, 383, 57-64.
2. Alzheimers Disease International. (2009). World Alzheimer Report [Online]. Available: http://www.alz.co.uk/research/files/WorldAlzheimerReport. pdf [Accessed 01.09.2010].
3. Alzheimers Disease International. (2010). World Alzheimer Report [Online]. Available: http://www.alz.org/documents/national/ World-Alzheimer- Report-2010.pdf [Accessed 01.12.2010].
4. Angelo RT, Cringan MS, Chamberlain DL, Stahl AJ, Haslouer SG, Goodrich CA. (2007). Residual effects of lead and zinc mining on freshwater mussels in the Spring River Basin (Kansas, Missouri, and Oklahoma, USA). Sci Total Environ, 384, 467-496.
5. Atkins DS, Basha MR, Zawia NH. (2003). Intracellular signaling pathways involved in mediating the effects of lead on the transcription factor Sp1. Int J Dev Neurosci, 21, 235-244.
6. Ballatore C, Lee VM, Trojanowski JQ. (2007). Tau-mediated neurodegeneration in Alzheimers disease and related disorders. Nat Rev Neurosci, 8, 663-672.
7. Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, Ge YW, Lahiri DK, Zawia NH. (2005). Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J, 19, 2083-2084.
8. Basha MR, Wei W, Brydie M, Razmiafshari M, Zawia NH. (2003). Lead-induced developmental perturbations in hippocampal Sp1 DNA-binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition. Int J Dev Neurosci, 21, 1-12.
9. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH. (2005). The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci, 25, 823-829.
10. Basun H, Forssell LG, Wetterberg L, Winblad B. (1991). Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimers disease. J Neural Transm Park Dis Dement Sect, 3, 231-258
11. Behl M, Zhang Y, Zheng W. (2009). Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure. Cerebrospinal Fluid Res, 6, 11.
12. Behl M, Zhang Y, Monnot AD, Jiang W, Zheng W. (2009). Increased beta-amyloid levels in the choroid plexus following lead exposure and the involvement of low-density lipoprotein receptor protein-1. Toxicol Appl Pharmacol, 240, 245-254.
13. Behl M, Zhang Y, Shi Y, Cheng J, Du Y, Zheng W. (2010). Lead-induced accumulation of beta-amyloid in the choroid plexus: role of low density lipoprotein receptor protein-1 and protein kinase C. Neurotoxicology, 31, 524-532.
14. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM. (2004). Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging, 25, 465-474.
15. Bertram L, Lill CM, Tanzi RE. (2010). The genetics of Alzheimer disease: back to the future. Neuron, 68, 270-281.
16. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, Cardozo- Pelaez F. (2006). Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J, 20, 788-790.
17. Braak H, Braak E. (1991). Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol, 82, 239-259.
18. Casas JS& Sordo, J. 2006. An overview of the historical importance, occurance, isolation, properties and applications of lead. In: Casas JS& Sordo J. (eds.) Lead. Amsterdam: Elsevier
19. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. (2004). Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol, 24, 865-874.
20. Citron BA, Dennis JS, Zeitlin RS, Echeverria V. (2008). Transcription factor Sp1 dysregulation in Alzheimers disease. J Neurosci Res, 86, 2499-2504.
21. Cory-Slechta DA. (1997). Relationships between Pb-induced changes in neurotransmitter system function and behavioral toxicity. Neurotoxicology, 18, 673-688.
22. Crossgrove JS, Li GJ, Zheng W. (2005). The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood), 230, 771-776.
23. Davey FD, Breen KC. (1998). The interaction between chronic lowlevel lead and the amyloid beta precursor protein. Amyloid, 5, 90-98.
24. De La Monte SM& Wands JR (2008). Alzheimers disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (Online), 2, 1101-1113.
25. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med, 9, 907-913.
26. Devi CB, Reddy GH, Prasanthi RP, Chetty CS, Reddy GR. (2005). Developmental lead exposure alters mitochondrial monoamine oxidase and synaptosomal catecholamine levels in rat brain. Int J Dev Neurosci, 23, 375-381.
27. Devoto P, Flore G, Ibba A, Fratta W, Pani L. (2001). Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus accumbens dopamine release as studied by brain microdialysis. Toxicol Lett, 121, 199-206.
28. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG. (2006). RAGE, LRP-1, and amyloid-beta protein in Alzheimers disease. Acta Neuropathol, 112, 405-415.
29. Egerházi A, Berecz R, Bartók E, Degrell I. (2007). Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimers disease. Prog Neuropsychopharmacol Biol Psychiatry, 31, 746-751.
30. Engle MJ, Volpe JJ. (1990). Glutamine synthetase activity of developing astrocytes is inhibited in vitro by very low concentrations of lead. Brain Res Dev Brain Res, 55, 283-287.
31. Ercal N, Gurer-Orhan H, Aykin-Burns N. (2001). Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem, 1, 529-539.
32. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA, 100, 4162-4167.
33. Flicker L. (2010). Modifiable lifestyle risk factors for Alzheimers disease. J Alzheimers Dis, 20, 803-811.
34. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. (1998). Prevention of dementia in randomised doubleblind placebo-controlled Systolic Hypertension in Europe (Syst- Eur) trial. Lancet, 352, 1347-1351.
35. Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L. (2009). Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimers disease. Dement Geriatr Cogn Disord, 28, 88-94.
36. Gerhardsson L, Lundh T, Minthon L, Londos E. (2008). Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimers disease. Dement Geriatr Cogn Disord, 25, 508-515.
37. Gläser C, Schulz S, Handschug K, Huse K, Birkenmeier G. (2004). Genetic and functional characteristics of the human in vivo LRP1/ A2MR receptor suggested as a risk marker for Alzheimers disease and other complex (degenerative) diseases. Neurosci Res, 50, 85-101.
38. Glass TA, Bandeen-Roche K, McAtee M, Bolla K, Todd AC, Schwartz BS. (2009). Neighborhood psychosocial hazards and the association of cumulative lead dose with cognitive function in older adults. Am J Epidemiol, 169, 683-692.
39. Godwin HA. (2001). The biological chemistry of lead. Curr Opin Chem Biol, 5, 223-227.
40. Goldstein GW. (1993). Evidence that lead acts as a calcium substitute in second messenger metabolism. Neurotoxicology, 14, 97-101.
41. Gong Z, Evans HL. (1997). Effect of chelation with mesodimercaptosuccinic acid (DMSA) before and after the appearance of lead-induced neurotoxicity in the rat. Toxicol Appl Pharmacol, 144, 205-214.
42. Grandjean P, Kon SH. (1981). Lead exposure of welders and bystanders in a ship repair yard. Am J Ind Med, 2, 65-70.
43. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. (2003). Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol, 60, 753-759.
44. Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, Zheng W, Du Y. (2011). Lead exposure increases levels of ß-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neurosci Lett, 490, 16-20.
45. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. (2010). Food combination and Alzheimer disease risk: a protective diet. Arch Neurol, 67, 699-706.
46. Guilarte TR, Toscano CD, McGlothan JL, Weaver SA. (2003). Environmental enrichment reverses cognitive and molecular deficits induced by developmental lead exposure. Ann Neurol, 53, 50-56.
47. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. (2010). Biomarkers for Alzheimers disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov, 9, 560-574.
48. Hanson EH, Imperatore G, Burke W. (2001). HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol, 154, 193-206.
49. Haraguchi T, Ishizu H, Takehisa Y, Kawai K, Yokota O, Terada S, Tsuchiya K, Ikeda K, Morita K, Horike T, Kira S, Kuroda S. (2001). Lead content of brain tissue in diffuse neurofibrillary tangles with calcification (DNTC): the possibility of lead neurotoxicity. Neuroreport, 12, 3887-3890.
50. Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science, 297, 353-356
51. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. (2003).Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol, 60, 1119-1122.
52. Heicklen-Klein A, Ginzburg I. (2000). Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem, 75, 1408-1418.
53. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA, 91, 3270-3274.
54. Hernberg S. (2000). Lead poisoning in a historical perspective. Am J Ind Med, 38, 244-254.
55. Herz J, Chen Y, Masiulis I, Zhou L. (2009). Expanding functions of lipoprotein receptors. J Lipid Res, 50 Suppl, S287-S292.
56. Herz J, Strickland DK. (2001). LRP: a multifunctional scavenger and signaling receptor. J Clin Invest, 108, 779-784.
57. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. (2007). How common are the "common" neurologic disorders? Neurology, 68, 326-337.
58. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimers disease. Ann Neurol, 51, 783-786.
59. Hu H, Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, Rotnitzky A. (1996). Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. The normative aging study. Am J Epidemiol, 144, 749-759.
60. Hu H, Shih R, Rothenberg S, Schwartz BS. (2007). The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect, 115, 455-462.
61. Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV. (2005). Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimers disease. J Neurosci, 25, 5217-5224.
62. Janssen I, Boyce WF, Simpson K, Pickett W. (2006). Influence of individual - and area-level measures of socioeconomic status on obesity, unhealthy eating, and physical inactivity in Canadian adolescents. Am J Clin Nutr, 83, 139-145.
63. Kazantzis G, Smith MA, Grant LD, Sors AI (1989). Lead: ancient metal-modern menace. Lead Exposure and Child Development-An International Perspective (M.A., Smith, L.D. Grant, and A.I. Sors, eds.), Kluwer Academic Press, Boston, 119-128.
64. Lasley SM, Green MC, Gilbert ME. (1999). Influence of exposure period on in vivo hippocampal glutamate and GABA release in rats chronically exposed to lead. Neurotoxicology, 20, 619-629.
65. Lee S, Kawachi I, Berkman LF, Grodstein F. (2003). Education, other socioeconomic indicators, and cognitive function. Am J Epidemiol, 157, 712-720.
66. Lee VM, Goedert M, Trojanowski JQ. (2001). Neurodegenerative tauopathies. Annu Rev Neurosci, 24, 1121-1159.
67. Li N, Yu ZL, Wang L, Zheng YT, Jia JX, Wang Q, Zhu MJ, Liu XL, Xia X, Li WJ. (2010). Increased tau phosphorylation and beta amyloid in the hipocampus of mouse pups by early life lead exposure. Acta Biol Hung, 61, 123-134.
68. Li YY, Chen T, Wan Y, Xu SQ. (2010). Lead exposure in pheochromocytoma cells induces persistent changes in amyloid precursor protein gene methylation patterns. Environ Toxicol. 2010 Nov 29 [Epub ahead of print]
69. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. (2005). Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci, 22, 1942-1950.
70. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. (2007). Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron, 56, 66-78.
71. Luchsinger JA. (2010). Diabetes, related conditions, and dementia. J Neurol Sci, 299, 35-38.
72. Markesbery WR, Carney JM. (1999). Oxidative alterations in Alzheimers disease. Brain Pathol, 9, 133-146.
73. Miodovnik A, Landrigan PJ. (2009). The U.S. Food and Drug Administration risk assessment on lead in women's and children's vitamins is based on outdated assumptions. Environ Health Perspect, 117, 1021-1022.
74. Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. (2000). Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet, 93, 58-66.
75. Momcilovic B, Alkhatib HA, Duerre JA, Cooley M, Long WM, Harris TR, Lykken GI. (2001). Environmental lead-210 and bismuth-210 accrue selectively in the brain proteins in Alzheimer disease and brain lipids in Parkinson disease. Alzheimer Dis Assoc Disord, 15, 106-115.
76. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol, 58, 397-405.
77. Muldoon SB, Cauley JA, Kuller LH, Morrow L, Needleman HL, Scott J, Hooper FJ. (1996). Effects of blood lead levels on cognitive function of older women. Neuroepidemiology, 15, 62-72.
78. Mungarro-Menchaca X, Ferrera P, Morán J, Arias C. (2002). beta- Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res, 68, 89-96.
79. Mutter J, Curth A, Naumann J, Deth R, Walach H. (2010). Does inorganic mercury play a role in Alzheimers disease? A systematic review and an integrated molecular mechanism. J Alzheimers Dis, 22, 357-374.
80. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 53, 695-699.
81. Niklowitz WJ, Mandybur TI. (1975). Neurofibrillary changes following childhood lead encephalopathy. J Neuropathol Exp Neurol, 34, 445-455.
82. Nordberg M, Winblad B, Fratiglioni L, Basun H. (2000). Lead concentrations in elderly urban people related to blood pressure and mental performance: results from a population-based study. Am J Ind Med, 38, 290-294.
83. Oortgiesen M, van Kleef RG, Bajnath RB, Vijverberg HP. (1990). Nanomolar concentrations of lead selectively block neuronal nicotinic acetylcholine responses in mouse neuroblastoma cells. Toxicol Appl Pharmacol, 103, 165-174.
84. Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A. (1995). Prevalence of Alzheimers disease and vascular dementia: association with education. The Rotterdam study. BMJ, 310, 970-973.
85. Patil AJ, Bhagwat VR, Patil JA, Dongre NN, Ambekar JG, Jailkhani R, Das KK. (2006). Effect of lead (Pb) exposure on the activity of superoxide dismutase and catalase in battery manufacturing workers (BMW) of Western Maharashtra (India) with reference to heme biosynthesis. Int J Environ Res Public Health, 3, 329-337.
86. Payton M, Riggs KM, Spiro A 3rd, Weiss ST, Hu H. (1998). Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol, 20, 19-27.
87. Petersen RC. (2004). Mild cognitive impairment as a diagnostic entity. J Intern Med, 256, 183-194.
88. Petersen RC, Negash S. (2008). Mild cognitive impairment: an overview. CNS Spectr, 13, 45-53.
89. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch Neurol, 56, 303-308.
90. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR. (2003). Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimers disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet, 119B, 48-53.
91. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem, 273, 32730-32738.
92. Querfurth HW, LaFerla FM. (2010). Alzheimers disease. N Engl J Med, 362, 329-344.
93. Quig D. (1998). Cysteine metabolism and metal toxicity. Altern Med Rev, 3, 262-270.
94. Rabinowitz MB. (1991). Toxicokinetics of bone lead. Environ Health Perspect, 91, 33-37.
95. Rabinowitz MB, Wetherill GW, Kopple JD. (1976). Kinetic analysis of lead metabolism in healthy humans. J Clin Invest, 58, 260-270.
96. Rahman A, Brew BJ, Guillemin GJ. (2011). Lead dysregulates serine/ threonine protein phosphatases in human neurons. Neurochem Res, 36, 195-204.
97. Reddy CC, Scholz RW, Massaro EJ. (1981). Cadmium, methylmercury, mercury, and lead inhibition of calf liver glutathione S-transferase exhibiting selenium-independent glutathione peroxidase activity. Toxicol Appl Pharmacol, 61, 460-468.
98. Rehman SU (1984). Lead-induced regional lipid peroxidation in brain. Toxicol Lett, 21, 333-337.
99. Reinhard C, Hébert SS, De Strooper B. (2005). The amyloid-beta precursor protein: integrating structure with biological function. EMBO J, 24, 3996-4006.
100. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. (2002). An iron-responsive element type II in the 59-untranslated region of the Alzheimers amyloid precursor protein transcript. J Biol Chem, 277, 45518-45528.
101. Sanders T, Liu Y, Buchner V, Tchounwou PB. (2009). Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health, 24, 15-45.
102. Schwartz BS, Stewart WF. (2007). Lead and cognitive function in adults: a questions and answers approach to a review of the evidence for cause, treatment, and prevention. Int Rev Psychiatry, 19, 671-692.
103. Selkoe DJ. (2001). Alzheimers disease: genes, proteins, and therapy. Physiol Rev, 81, 741-766.
104. Selkoe DJ. (2002). Alzheimers disease is a synaptic failure. Science, 298, 789-791.
105. Silbergeld EK, Schwartz J, Mahaffey K. (1988). Lead and osteoporosis: mobilization of lead from bone in postmenopausal women. Environ Res, 47, 79-94.
106. Silbergeld EK. (1992). Mechanisms of lead neurotoxicity, or looking beyond the lamppost. FASEB J, 6, 3201-3206.
107. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. (2005).
108. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci, 8, 1051-1058.
109. Somashekaraiah BV, Padmaja K, Prasad AR. (1992). Lead-induced lipid peroxidation and antioxidant defense components of developing chick embryos. Free Radic Biol Med, 13, 107-114.
110. Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. (2002). ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect, 110, 501-505.
111. Tong S, von Schirnding YE, Prapamontol T. (2000). Environmental lead exposure: a public health problem of global dimensions. Bull World Health Organ, 78, 1068-1077.
112. Toscano CD, Guilarte TR. (2005). Lead neurotoxicity: from exposure to molecular effects. Brain Res Brain Res Rev, 49, 529-554.
113. Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, Ivnik RJ, Thibodeau SN. (1994). Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet, 54, 643-649.
114. US Census Bureau. (2000). National Population Projections-Summary Tables 1998-2000 [Online]. Available: http://www.census. gov/population/www/ projections/natsum-T3.html [Accessed September 02, 2010].
115. van Praag H, Kempermann G, Gage FH. (2000). Neural consequences of environmental enrichment. Nat Rev Neurosci, 1, 191-198.
116. Van Wijngaarden E, Winters PC, Cory-Slechta DA. (2011). Blood lead levels in relation to cognitive function in older U.S. adults. Neurotoxicology, 32, 110-115.
117. Van Wijngaarden E, Campbell JR, Cory-Slechta DA (2009). Bone lead levels are associated with measures of memory impairment in older adults. Neurotoxicology, 30, 572-580.
118. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT. (2004). The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-Mrna 59-untranslated region. Ann N Y Acad Sci, 1035, 34-48.
119. Verghese PB, Castellano JM, Holtzman DM. (2011). Apolipoprotein E in Alzheimers disease and other neurological disorders. Lancet Neurol, 10, 241-252.
120. Verina T, Rohde CA, Guilarte TR. (2007). Environmental lead exposure during early life alters granule cell neurogenesis and morphology in the hippocampus of young adult rats. Neuroscience, 145, 1037-1047.
121. Villeda-Hernández J, Barroso-Moguel R, Méndez-Armenta M, Nava- Ruíz C, Huerta-Romero R, Ríos C. (2001). Enhanced brain regional lipid peroxidation in developing rats exposed to low level lead acetate. Brain Res Bull, 55, 247-251.
122. Waldron HA. (1973). Lead poisoning in the ancient world. Med Hist, 17, 391-399.
123. Wang FT, Hu H, Schwartz J, Weuve J, Spiro AS, Sparrow D, Nie H, Silverman EK, Weiss ST, Wright RO. (2007). Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. Environ Health Perspect, 115, 1210-1215.
124. Wang L, Luo L, Luo YY, Gu Y, Ruan DY. (2007). Effects of Pb2+ on muscarinic modulation of glutamatergic synaptic transmission in rat hippocampal CA1 area. Neurotoxicology, 28, 499-507.
125. Wechsler D. (1997). Wechsler adult intelligence scale-III (WAIS-III), San Antonio, TX, Harcourt Brace and Company
126. Weisskopf MG, Wright RO, Schwartz J, Spiro A 3rd, Sparrow D, Aro A, Hu H. (2004). Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol, 160, 1184-1193.
127. Weisskopf MG, Proctor SP, Wright RO, Schwartz J, Spiro A 3rd, Sparrow D, Nie H, Hu H. (2007). Cumulative lead exposure and cognitive performance among elderly men. Epidemiology, 18, 59-66.
128. Weuve J, Korrick SA, Weisskopf MG, Weisskopf MA, Ryan LM, Schwartz J, Nie H, Grodstein F, Hu H. (2009). Cumulative exposure to lead in relation to cognitive function in older women. Environ Health Perspect, 117, 574-580.
129. White RF, Diamond R, Proctor S, Morey C, Hu H. (1993). Residual cognitive deficits 50 years after lead poisoning during childhood. Br J Ind Med, 50, 613-622.
130. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. (2009). Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA, 301, 1565-1572.
131. Wright RO, Tsaih SW, Schwartz J, Spiro A 3rd, McDonald K, Weiss ST, Hu H. (2003). Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology, 14, 713-718.
132. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, Zawia NH. (2008). Alzheimers disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci, 28, 3-9.
133. Yun SW, Hoyer S. (2000). Effects of low-level lead on glycolytic enzymes and pyruvate dehydrogenase of rat brain in vitro: relevance to sporadic Alzheimers disease? J Neural Transm, 107, 355-368.
134. Zawia NH, Sharan R, Brydie M, Oyama T, Crumpton T. (1998). Sp1 as a target site for metal-induced perturbations of transcriptional regulation of developmental brain gene expression. Brain Res Dev Brain Res, 107, 291-298.
135. Zhao Q, Slavkovich V, Zheng W. (1998). Lead exposure promotes translocation of protein kinase C activities in rat choroid plexus in vitro, but not in vivo. Toxicol Appl Pharmacol, 149, 99-106.
136. Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. (2010). Lowdensity lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimers amyloid ß-peptide elimination from the brain. J Neurochem, 115, 1077-1089.